Taihe Group, Inc. (TIHE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Taihe Group, Inc. (TIHE) trades at $1.00. Taihe Group, Inc. previously operated as a commercial laboratory providing oncology testing services. Currently, the company does not have significant operations. Market cap: $71.85M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for TIHE: TIHE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TIHE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TIHE: 1/1 perspectives are bearish.
How is this calculated? →Taihe Group, Inc. (TIHE) Healthcare & Pipeline Overview
Taihe Group, Inc., formerly NuOncology Labs, is an Arizona-based company that previously offered predictive chemosensitivity and immunotherapy tests. With a market capitalization of $71.85M, the company currently does not have significant operations within the medical diagnostics and research sector, operating on the OTC market.
What Is the Investment Thesis for TIHE?
Taihe Group, Inc. presents a speculative investment profile given its current lack of significant operations and its history as a commercial laboratory specializing in oncology testing. With a market capitalization of $71.85M and a negative P/E ratio of -1428.57, the company's financial metrics reflect its operational status. The beta of 1.23 suggests a higher volatility compared to the market. Any investment consideration should heavily weigh the risks associated with OTC-traded companies and the uncertainty surrounding Taihe Group's future business plans. Potential catalysts would depend on the company's ability to identify and execute a new business strategy.
Based on FMP financials and quantitative analysis
TIHE Key Highlights
- Market capitalization of $71.85M indicates a micro-cap company.
- Negative P/E ratio of -1428.57 reflects current lack of profitability.
- Beta of 1.23 suggests the stock is more volatile than the market average.
- The company does not currently offer a dividend, indicating a focus on reinvestment or potential financial constraints.
- Formerly NuOncology Labs, the company changed its name to Taihe Group, Inc. in April 2022.
Who Are TIHE's Competitors?
TIHE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOGF Biocartis Group N.V. | $0.66 | -85.33% | $65.41M | 52 |
| EEOIF Elegance Optical International Holdings Limited | $0.07 | +0.00% | $63.38M | 46 |
| EOFBY Ecofibre Limited | $0.84 | +0.00% | $73.67M | 40 |
| ETXPF E-therapeutics Plc | $0.13 | +0.00% | $75.96M | 38 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.05M | 64 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TIHE's Key Strengths?
- Previous experience in oncology testing.
- Established as a legal entity since 1994.
- Potential for re-entry into the diagnostics market.
What Are TIHE's Weaknesses?
- Currently lacks significant operations.
- Limited financial resources.
- Uncertainty regarding future business strategy.
- Small number of employees (3).
What Could Drive TIHE Stock Higher?
- Potential acquisition of a new diagnostic technology could revitalize the company.
- Strategic partnership with a research institution could lead to new product development.
- Exploration of opportunities in emerging markets could drive future growth.
What Are the Key Risks for TIHE?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition in the medical diagnostics industry.
- Stringent regulatory requirements and the need for approvals.
- Limited financial resources and lack of current operations.
- Risk associated with OTC market trading.
What Are the Growth Opportunities for TIHE?
- Acquisition of a Promising Diagnostic Technology: Taihe Group could acquire a novel diagnostic technology or platform to re-enter the market. The global molecular diagnostics market, estimated at $12.5 billion in 2024, is projected to reach $18.9 billion by 2029, growing at a CAGR of 8.6%. A successful acquisition could provide a clear growth path within 12-24 months.
- Strategic Partnership with a Research Institution: Partnering with a leading research institution could provide Taihe Group with access to cutting-edge research and development capabilities. This could lead to the co-development of new diagnostic tests or therapies, creating a revenue stream within 3-5 years. Such partnerships are common in the healthcare sector and can significantly de-risk innovation efforts.
- Geographic Expansion into Emerging Markets: Taihe Group could explore opportunities to expand its operations into emerging markets with unmet diagnostic needs. The Asia-Pacific region, for example, is experiencing rapid growth in healthcare spending and demand for advanced diagnostics. Entering these markets could provide a significant growth boost within 2-3 years.
- Development of Personalized Medicine Solutions: With the rise of personalized medicine, Taihe Group could focus on developing diagnostic tests tailored to individual patients based on their genetic profiles. This approach has the potential to improve treatment outcomes and reduce healthcare costs. The personalized medicine market is expected to reach $2.4 trillion by 2030, presenting a substantial opportunity.
- Focus on Telehealth and Remote Monitoring: As telehealth gains traction, Taihe Group could develop diagnostic tools and services that can be used remotely, allowing patients to monitor their health from home. This could improve access to care and reduce the burden on healthcare systems. The global telehealth market is projected to reach $55.5 billion by 2027, growing at a CAGR of 25.9%.
What Opportunities Does TIHE Have?
- Acquisition of new diagnostic technologies.
- Strategic partnerships with research institutions.
- Expansion into emerging markets.
- Development of personalized medicine solutions.
What Threats Does TIHE Face?
- Intense competition in the diagnostics industry.
- Stringent regulatory requirements.
- Rapid technological advancements.
- Potential for obsolescence of existing technologies.
What Are TIHE's Competitive Advantages?
- Historically, specialized knowledge in predictive oncology testing.
- Potential intellectual property related to testing methods (if any).
- Established relationships with oncologists (if any).
What Does TIHE Do?
Taihe Group, Inc., based in Scottsdale, Arizona, was originally incorporated in 1994. Until April 2022, when it changed its name from NuOncology Labs, the company operated as a commercial laboratory. Its primary business involved providing predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues, along with other oncological laboratory testing services and products. These services aimed to assist oncologists in making informed treatment decisions for cancer patients. However, as of 2026, Taihe Group, Inc. does not have significant ongoing operations. The company's historical focus on specialized oncology testing reflects an attempt to carve out a niche in the competitive healthcare diagnostics market. The shift away from active operations raises questions about the company's future direction and strategic alternatives.
What Products and Services Does TIHE Offer?
- Formerly operated as a commercial laboratory.
- Provided predictive chemosensitivity tests.
- Offered immunotherapy predictive tests.
- Conducted oncological laboratory testing.
- Developed related products for oncology testing.
- Aimed to assist oncologists in treatment decisions.
How Does TIHE Make Money?
- Historically, generated revenue through fees for diagnostic testing services.
- Potentially licensing or selling proprietary testing technologies.
- May have pursued research grants or funding for test development.
What Industry Does TIHE Operate In?
Taihe Group, Inc. previously operated within the medical diagnostics and research industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. Companies in this space develop and market diagnostic tests, imaging technologies, and research tools used in disease detection, monitoring, and treatment. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in genomics and personalized medicine. Competitors include larger, more established players as well as smaller, specialized firms. Given Taihe Group's current lack of significant operations, its future positioning within this landscape is uncertain.
Who Are TIHE's Key Customers?
- Oncologists and cancer treatment centers.
- Hospitals and medical clinics.
- Research institutions conducting cancer research.
Company Profile
Taihe Group, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Scottsdale, US. The company is led by CEO Yan Ping Sheng. TIHE has traded publicly since 1998.
Taihe Group, Inc. (TIHE) Valuation Context
Valued at $71.85M, TIHE is classified as a micro-cap stock.
ROE 1%Key Financial Metrics
Return on equity for Taihe Group, Inc. stands at 0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Taihe Group, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TIHE Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Social sentiment has shifted positively, with community discussions highlighting new partnerships that could enhance revenue streams.
- Analysts are noting improvements in operational efficiency, which could lead to better profit margins moving forward.
- Market perception is buoyed by favorable regulatory developments that may benefit the industry as a whole.
Bear Case
- Concerns over supply chain disruptions have emerged, leading to skepticism about the company's ability to meet demand.
- Recent bearish sentiment in social discussions reflects worries about increasing competition in the sector, potentially impacting market share.
- Some analysts express caution regarding the company's debt levels, raising questions about financial stability in a fluctuating market.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's growth trajectory in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TIHE Latest News
No recent news available for TIHE.
TIHE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TIHE.
Price Targets
Wall Street price target analysis for TIHE.
TIHE MoonshotScore
What does this score mean?
The MoonshotScore rates TIHE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yan Ping Sheng
Managing Director
Yan Ping Sheng is the Managing Director of Taihe Group, Inc. and oversees the company's operations with a team of 3 employees. Information regarding Mr. Sheng's prior experience and educational background is not available. As Managing Director, Mr. Sheng is responsible for guiding the strategic direction of the company, although the company currently does not have significant operations.
Track Record: Given the company's current lack of significant operations, it is difficult to assess Mr. Sheng's track record. His leadership will be crucial in determining whether Taihe Group, Inc. can successfully re-enter the diagnostics market or pursue alternative business opportunities.
TIHE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Taihe Group, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial information available and may be subject to greater risks compared to companies listed on national exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Uncertainty regarding the company's future prospects.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business plan and prospects for future growth.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been incorporated since 1994.
- Previously operated as a commercial laboratory.
- Maintained its corporate existence.
TIHE Healthcare Stock FAQ
What does Taihe Group, Inc. do?
Taihe Group, Inc. formerly operated as NuOncology Labs, a commercial laboratory providing predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. These services were designed to aid oncologists in making informed treatment decisions for cancer patients. However, as of 2026, Taihe Group, Inc. does not have significant operations, and its future business direction is uncertain. The company's historical focus was on specialized oncology testing within the healthcare diagnostics market.
What do analysts say about TIHE stock?
As of March 18, 2026, there is limited to no analyst coverage available for Taihe Group, Inc. (TIHE), likely due to its OTC listing and lack of significant operations. Key valuation metrics such as revenue projections and earnings estimates are unavailable. Any investment decision would need to be based on independent due diligence and an assessment of the company's potential to re-enter the diagnostics market or pursue alternative business opportunities, considering the inherent risks of OTC-traded stocks.
What are the main risks for TIHE?
The main risks for Taihe Group, Inc. include its current lack of significant operations, limited financial resources, and the uncertainty surrounding its future business strategy. As an OTC-traded company, TIHE is subject to lower disclosure requirements and greater price volatility compared to companies listed on national exchanges. Additionally, the company faces potential competition from established players in the medical diagnostics industry and the need to comply with stringent regulatory requirements.
What are the key factors to evaluate for TIHE?
Evaluate TIHE on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TIHE data refresh on this page?
TIHE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TIHE's recent stock price performance?
Taihe Group, Inc. (TIHE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Previous experience in oncology testing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TIHE overvalued or undervalued right now?
Valuing Taihe Group, Inc. (TIHE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TIHE?
Before investing in Taihe Group, Inc. (TIHE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and lack of significant operations.